Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

TYRABullishEarningsShort Term

High materiality8/10

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

StockNews.AIAug 4, 4:05 PM EDT1 source

Trading thesisImportance 8/10

Long TYRA ahead of Sept 2026 SURF302 data and early-2027 BEACH301 readouts.

AI summary

What happened and why it matters

TYRA reported Q2 2026 results and highlighted Dabogratinib progress across SURF303, SURF302, and BEACH301. Sept 2026 will bring SURF302 initial data, with BEACH301 sentinel results targeted by end-2027. A new EVP, Jonathan Day, was appointed to accelerate skeletal dysplasia programs; TYRA also reiterated a cash runway into 2H-2028 with $353.9M on hand.

SURF302 data readout due Sep 2026; potential near-term re-rating on safety/efficacy signals.
BEACH301 safety sentinel results expected end of Q1 2027; fifth dose level expanded.
ATM financing up to $250M may influence share count and dilution risk.
Cash runway into 2H 2028 supports continued development and data generation.

Sentiment rationale

Upcoming data readouts (Sept 2026 SURF302; early-2027 BEACH301) and a strengthened balance sheet via a larger ATM capacity could drive a re-rating if data are favorable, though Phase 2 results carry typical execution risk and dilution concerns from ATM activity.

Key facts

01
SURF302 Ph2 data due Sept 2026; enrollment >40.
02
BEACH301 sentinel results end of Q1 2027; fifth dose level opened; ~25 children.
03
Jonathan Day appointed EVP, Clinical Development to lead skeletal dysplasia strategy.
04
Cash, cash equivalents and marketable securities: $353.9M; runway into 2H 2028.
05
Dabogratinib 3x3 strategy targets 3 Phase 2 pivotal studies: LG-UTUC, IR NMIBC, ACH.

Corporate Developments

Category: Corporate Developments. The highlights (leadership change, financing actions, and pipeline milestones) shape TYRA's near- to mid-term valuation and risk profile rather than immediate product approvals.